In 2006, DIA was among the first organizations to recognize the importance of patient involvement in drug development and launched its first Patient Fellowship Program. Since then, the role patients can play in therapeutic product R&D has exploded. DIA continues to lead the way, providing input and insights into the evolution of therapeutic product development, and driving towards improved health and well-being throughout the world. Read On.


DIA Considerations Guide: Download Now

Considerations Guide

Developed as part of DIA’s Study of Patient-Centric Initiatives in Drug Development, the Considerations Guide was designed as a practical resource for pharmaceutical companies as you launch or advance patient-centered initiatives that support health care product research and development.

Get the Guide

Patient Engagement Study: Download Now

Patients Webinar

Read this executive summary and detailed study results that include key insights in the following areas: adoption of patient-centric initiatives by pharmaceutical and biotech companies, barriers to adoption of patient-centric initiatives, comparative analytics and results of patient-centric initiatives.

Download Study Reports

DIA Releases Results of Patient Engagement in Drug Development Study

The DIA study, conducted in partnership with Tufts University, found that half of pharmaceutical and biotech companies surveyed implementing patient-centric drug development initiatives; but measurement and success vary widely. However, barriers such as risk tolerance, lack of staff, time, and budget have constrained implementation. Furthermore, quantifying results is challenging as there is limited comparative analytic data that support specific methods of patient-centricity.

Read the Full Release

Patient Engagement

Visual Model of Patient Engagement

Join the Patient Engagement Conversation

Patient Engagement Community

DIA Members interact in this exclusive online forum, hosting engaging discussions, webinars and connecting with Patient Engagement stakeholders globally.  Already a DIA Member? Join the DIA Patient Engagement Community.

Why DIA Membership?

DIA 2017 Annual Meeting

McCormick Place

Make Mine Mobile: Bring the Trial to the Patient

At DIA 2016, Joseph Kim (Eli Lilly and Company) challenged the clinical trial industry to figure out what the banking industry…

How Far Can Regulators Drive Patient Engagement?

Patient engagement is a full-fledged global movement driven not only by patients but by agencies such as the US FDA and the UK…

FDA Commissioner Califf Speaks with "Global Forum"

By Alberto Grignolo, PhD, Global Forum Deputy Editor

After appearing in the DIA 2016 Annual Meeting panel discussion International Regulatory...

Past, Present, Possibilities: DIA & Patient Engagement

By Yves Juillet, PhD

Dr. Yves Juillet has been involved with DIA since 1990 and was the impetus behind the association’s first formal steps…

How to Assess PAO’s Readiness to Collaborate

By Elizabeth Lincoln, DIA Global Director of Engagement

The ultimate purpose of any medical product is to meet the needs of the patient. In the past few years the idea that patient need…

EUPATI Toolbox: DIA Works for Patients

On January 27, 2016. the European Patients’ Academy on Therapeutic Innovation – EUPATI – unveiled its new online Toolbox on…

Clinical Trials & The Disney Effect

By John Reites, Head of Digital Health Acceleration, Quintiles

Today’s consumers expect seamless, value-driven experiences when they engage with a brand. From buying products online, to…

Collaboration Benefits Rare Disease Research & Patients

By Vinciane Pirard, MD, DIA Global Forum Content Editor for Rare Diseases & Unmet Medical Needs

Rare diseases don’t share a common etiology or biology; they don’t affect the same organs or present with similar symptoms; but…

The Evolution of Patient Engagement at FDA

By John Whyte, MD, Director, CDER’s Professional Affairs & Stakeholder Engagement Staff

The drug approval process has traditionally relied heavily on scientific evidence for safety and efficacy. In a recent evolution…